This $465,404 Project Grant awarded by the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) to Case Western Reserve University (along with its affiliation University Hospitals of Cleveland) supports research into the role of cyclin D1 and the FBXO4 E3 ligase complex in driving head and neck squamous cell carcinomas (HNSCC).
The key objectives are to: 1) Determine how the p53R172H mutation cooperates with cyclin D1 to promote HNSCC development in vivo; 2) Elucidate the mechanisms by which FBXO4 regulates the tumor suppressor LKB1 and impacts HNSCC; and 3) Evaluate the therapeutic potential of targeting glutamine metabolism in HNSCC with dysregulated FBXO4-cyclin D/CDK4. This 5-year project aims to advance the understanding of how cyclin D1 and metabolic reprogramming contribute to HNSCC pathogenesis, with the goal of identifying new treatment strategies.
Generated 1/28/25, 8:41 AM